Article
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Hormones & cancer - 1 Jun 2016
Yarchoan Mark, Ma Changqing, Troxel Andrea B, Stopenski Stephen J, Tang Waixing, Cohen Aaron B, Pappas-Paxinos Marina, Johnson Burles A, Chen Emerson Y, Feldman Michael D, Brose Marcia S
Abstract excerpt
Sorafenib has an antitumor activity in patients with radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC). Prior research has implicated signaling through the MAPK and AKT/PI3K pathways in the progression of DTC. To assess whether the activity of these pathways is predictive of response to sorafenib, we retrospectively studied molecular tumor markers from these two pathways from a phase 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.